Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity
Wake Forest University Health Sciences · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Virginia · NCT07227051
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 300
- US sites recruiting
- 1
- Study start
- January 26, 2026
- Record last updated
- June 24, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this research study is to learn how to best provide weekly feedback on individual progress toward intervention goals during a weight loss program.
Being studied: Feedback on Calorie Goal Attainment; Feedback on Dietary Quality; Feedback on Physical Activity Goal Attainment; Goal Setting Prompt
Conditions: Obesity & Overweight; Obesity (Disorder)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age greater than or equal to 18 years
- BMI greater than or equal to 25.0 kg/m2
- Weight less than or equal to 175 kg (due to scale limit)
- Own a smartphone compatible with Fitbit (e.g., an Apple iPhone running iOS 16.4 or higher or Android smartphone running Android 11 or higher) with a cellular and data plan
Exclusion Criteria
- Weight greater than 175 kg (due to a weight limit of the study-provided scale)
- Smartphone device owned deemed incompatible with the Fitbit App
- History of bariatric surgery or plans to obtain bariatric surgery during the study period
- Current use of weight loss medications, or use of weight loss medications in the 6 months prior to initial pre-screening
- Currently participating in a weight-loss program
- Weight loss of greater than or equal to 10 lbs in the 6 months prior to initial pre-screening
- Physical limitations that prevent walking at a brisk pace for at least 10 minutes without stopping
- Use of a pacemaker or other implanted medical device
- Currently pregnant
- Currently breastfeeding
- Less than 1-year post-partum
- Plans to become pregnant within the study period
- Lack of written confirmation that the potential participant has discussed study participation with their physician if they have been diagnosed with diabetes, hypertension, or has have a history of coronary heart disease
- One or more study participants living in the household (enrollment limited to one participant per household)
- Medical conditions that contraindicate weight loss or prevent completion of the study (e.g., current diagnosis of cancer or terminal illness, dementia, etc.)
- Recent (in the past 6 months) changes in medications that affect weight
- Self-reported eating disorder within past 5 years
- Unable to complete the 17-week study (due to plans to relocate during the study period, etc.)
- Unable or unwilling to provide informed consent
- Unable to read English at the 5th grade level
- Unwilling to accept random assignment
- Unable or unwilling to download the study smartphone application, wear the physical activity monitor, or use the study e-scale
- Failure to complete baseline assessment measures
- Failure to complete at least 4 out of 6 days of self-monitoring dietary and weight self-monitoring during the behavioral run-in period
- Any other condition(s) which, in the opinion of the Principal Investigator, would adversely affect participation in the study
Recruiting US locations
Advocate Aurora Research Institute
Milwaukee, WI 53204
Site contact: Tejashri Ganbote, MBA, MBBS · 414-363-1229 · Tejashri.ganbote@aah.org
Study contacts (from the official record)
- Tejashri Ganbote, MBA, MBBS · 414-363-1229 · Tejashri.ganbote@aah.org
- Teace Markwalter, M.P.H., CHES · 866-271-7217 · bdw9cp@virginia.edu
Similar studies in Wisconsin
All weight loss studies in Wisconsin →- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Milwaukee, WI + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Milwaukee, WI + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Milwaukee, WI + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Wauwatosa, WI + 69 other US sites
- Eligibility basics
- Ages 18–99